Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alliance for Regenerative Medicine sees advanced therapies as pilot for EU's regular use of real-world evidence

As the European Commisson hammers out how best to incorporate real world evidence into the future of medicines regulation and reimbursement, the Alliance for Regenerative Medicine is calling for the EU bloc to use cell and gene therapies as a testing ground for the best ways to build and use a pan-European real-world evidence infrastructure.

On Wednesday the Alliance for Regenerative Medicine (ARM) published a position paper that says if the EU wants

Read the full 720 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers